Raytheon Technologies Corp vs Smith & Nephew plc — how do they compare? Raytheon Technologies Corp trades at $193.82 (market cap $261.85B), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Raytheon Technologies Corp is far larger — about 20.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.57%). Which is the better fit depends on your goals.
| RTX | SNN | |
|---|---|---|
Market Cap | $261.85B | $12.64B |
Sector | Industrials | Health |
52-Week High | $212.16 | $38.70 |
52-Week Low | $149.17 | $28.73 |
Enterprise Value | $293.97B | $15.41B |
Dividend Yield | 1.5% | 2.57% |
Signals from Pluang's Aura AI — not financial advice
RTX trades at $193.51, down 0.44% today, with a bullish technical signal and strong analyst support. Recent contract wins, including a $515 million Navy radar deal (PRNewsWire, June 3, 2026), and earnings beats in Q4 2025 and Q1 2026 highlight operational momentum. Revenue growth accelerated to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock faces resistance near $196-$199, with support at $192.
The outlook remains positive given defense spending tailwinds and production expansions, but elevated P/E of 36.48 poses valuation risk. Analysts project 10% upside to a $213 consensus target, with no sell ratings. Key risks include debt levels and geopolitical volatility affecting contracts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →